Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 2
1984 2
1985 1
1986 5
1987 2
1988 11
1989 4
1990 2
1991 2
1992 1
1993 1
1994 2
1997 1
1999 5
2000 7
2001 7
2002 6
2003 5
2004 6
2005 4
2006 3
2007 12
2008 3
2009 9
2010 7
2011 7
2012 10
2013 10
2014 19
2015 10
2016 12
2017 7
2018 8
2019 11
2020 11
2021 9
2022 8
2023 12
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, Maggiolo F, Degen O, Taylor S, Blair E, Man C, Wynne B, Oyee J, Underwood M, Curtis L, Bontempo G, van Wyk J. Llibre JM, et al. Among authors: maggiolo f. Clin Infect Dis. 2023 Feb 18;76(4):720-729. doi: 10.1093/cid/ciac130. Clin Infect Dis. 2023. PMID: 35235656 Free PMC article. Clinical Trial.
Efavirenz.
Maggiolo F. Maggiolo F. Expert Opin Pharmacother. 2007 Jun;8(8):1137-45. doi: 10.1517/14656566.8.8.1137. Expert Opin Pharmacother. 2007. PMID: 17516877 Review.
Pillars of long-term antiretroviral therapy success.
Taramasso L, Andreoni M, Antinori A, Bandera A, Bonfanti P, Bonora S, Borderi M, Castagna A, Cattelan AM, Celesia BM, Cicalini S, Cingolani A, Cossarizza A, D'Arminio Monforte A, D'Ettorre G, Di Biagio A, Di Giambenedetto S, Di Perri G, Esposito V, Focà E, Gervasoni C, Gori A, Gianotti N, Guaraldi G, Gulminetti R, Lo Caputo S, Madeddu G, Maggi P, Marandola G, Marchetti GC, Mastroianni CM, Mussini C, Perno CF, Rizzardini G, Rusconi S, Santoro M, Sarmati L, Zazzi M, Maggiolo F. Taramasso L, et al. Among authors: maggiolo f. Pharmacol Res. 2023 Oct;196:106898. doi: 10.1016/j.phrs.2023.106898. Epub 2023 Aug 28. Pharmacol Res. 2023. PMID: 37648103 Free article. Review.
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Orkin C, et al. Among authors: maggiolo f. Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0. Lancet HIV. 2020. PMID: 32504574 Clinical Trial.
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials.
Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, Maggiolo F, Stellbrink HJ, Yazdanpanah Y, Acosta R, Huang H, Hindman JT, Martin H, Baeten JM, Wohl D; GS-US-380-1489 and GS-US-380-1490 study investigators. Sax PE, et al. Among authors: maggiolo f. EClinicalMedicine. 2023 May 11;59:101991. doi: 10.1016/j.eclinm.2023.101991. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37200995 Free PMC article.
Enhancing care for people living with HIV: current and future monitoring approaches.
Maggiolo F, Bandera A, Bonora S, Borderi M, Calcagno A, Cattelan A, Cingolani A, Gianotti N, Lichtner M, Lo Caputo S, Madeddu G, Maggi P, Marchetti GC, Maserati R, Nozza S, Rusconi S, Zazzi M, Di Biagio A. Maggiolo F, et al. Expert Rev Anti Infect Ther. 2021 Apr;19(4):443-456. doi: 10.1080/14787210.2021.1823217. Epub 2020 Oct 15. Expert Rev Anti Infect Ther. 2021. PMID: 33054479 Free article. Review.
State of the Art of Dual Therapy in 2015.
Nozza S, Svicher V, Saracino A, d'Ettorre G, De Luca A, Maggiolo F, Bonora S, di Biagio A, Rusconi S, Mussini C. Nozza S, et al. Among authors: maggiolo f. AIDS Rev. 2015 Jul-Sep;17(3):127-34. AIDS Rev. 2015. PMID: 26450801 Review.
Adherence to and Forgiveness of 3TC/DTG in a Real-World Cohort.
Maggiolo F, Valenti D, Teocchi R, Comi L, Filippo ED, Rizzi M. Maggiolo F, et al. J Int Assoc Provid AIDS Care. 2022 Jan-Dec;21:23259582221101815. doi: 10.1177/23259582221101815. J Int Assoc Provid AIDS Care. 2022. PMID: 35695220 Free PMC article.
Abacavir + dolutegravir + lamivudine for the treatment of HIV.
Comi L, Maggiolo F. Comi L, et al. Among authors: maggiolo f. Expert Opin Pharmacother. 2016 Oct;17(15):2097-106. doi: 10.1080/14656566.2016.1232387. Epub 2016 Sep 13. Expert Opin Pharmacother. 2016. PMID: 27616133 Review.
229 results